Grow | Extract | Sell

Celadon’s 100,000 sq ft UK facility is licenced by UK regulators to cultivate high-THC cannabis and by MHRA to manufacture cannabinoid API to EU-GMP standard using its proprietary extraction technology. Post-legalisation in 2018 in the UK, cannabis-based medicines can be sold under the “specials” framework.

Grow | Extract | Sell

100,000 sq ft EU-GMP facility in UK 

Cultivation of high-THC cannabis

Controlled environment indoor cultivation designed for pharmaceutical-level quality and consistency

Extraction technology and manufacturing of API to EU-GMP standard 

Using API to develop novel medicines

LEARN MORE ABOUT OUR FACILITY

GROW

Celadon uses indoor cultivation hydroponic system in a fully controlled environment. Ensuring the highest quality and consistent pharmaceutical product.

There is no other cultivation facility of this kind in the UK, and the cultivation has been designed to grow to the highest-industry standard of Good Agricultural and Collection Practices (GACP).

Celadon’s Phase 1 cultivation rooms completed their seventh harvest in June 2022. The Phase 2 cultivation rooms will add significant capacity and aim to be operational in Q1 2023.

The facility is set up to deliver all aspects of the cultivation process; from seeds and tissue culture, to vegetation and flowering, to harvest, through to processing to API.

The cultivation rooms adopt the highest levels of technology, including smart lighting, environmental controls, hydroponic systems and plant/inventory tracking software.

Learn more about Celadon’s technology

EXTRACT

Celadon has a proprietary extraction technology that manufactures cannabinoid active pharmaceutical ingredients (APIs), and is one of a small number of companies globally of its kind to be awarded EU-GMP certification for a natural high-THC API.

Celadon’s proprietary API manufacturing process is led by its in-house Production and Quality teams to ensure the highest quality pharmaceutical product.

SELL

GMP licencing will enable Celadon to sell its high-THC API into the market for the development of pharmaceutical medicines, as well as enable Celadon to use its API in the development of its own finished medicines for both clinical trials and selling under the “specials” framework in the UK.

It will also enable Celadon to partner with world-leading pharmaceutical companies who wish to manufacture cannabinoid-based medicines, whether THC, CBD or other cannabinoids.

Receipt of this milestone licence will enable Celadon to sell its high-THC API into the manufacturing market for:

The development of pharmaceutical medicines

The development of finished medicines

Partnership with other world-leading pharmaceutical companies

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Medical Cannabis Market, Transparency Market Research May 2022

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Legalised in 2018

This will close in 0 seconds

Legalised in 37 States Limited Federal legalisation

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016 Rapid growth to >200k patients (2019-21)

This will close in 0 seconds

Legalised in 2001

This will close in 0 seconds

BUSINESS DESCRIPTION

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

This will close in 0 seconds

COUNTRY OF INCORPORATION/OPERATION

 

Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock
Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.

TIDM: CEL.L
ISIN: GB00BDQYGP38

There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.

This will close in 0 seconds

AIM SECURITIES IN ISSUE

 

The following information is correct as at 9th February 2023.

The Company’s issued share capital comprises

61,669,773 ordinary shares

Each with a nominal value of 1 pence

So far as the Company is aware, 69.8% of its issued share capital is not in public hands.

This will close in 0 seconds

Scroll to Top